![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, January 07, 2016 6:39:03 AM
The institutions represented by NCCN are some of the most prestigious and advanced global bodies that partner on development of medicines, run trials and treat patients.
I'm very confused reading some posts that look at this as an act of desperation or hedging of bets. Getting a product to be accepted into NCCN for evaluation and broad testing is a privilege - not an entitlement. The people who do the work are scientists, the best in the world, who do not take their work lightly and absolutely do not see themselves as assembly line workers just pushing the next product through its paces while collecting a salary. They spend their lives looking for cures and ways to help fight disease. They are never the dumpling grounds for a company's molecule desperately looking for a problem to solve...
So - yes. This provides both an insurance policy for high integrity and access to the basket of modern meds that various pharmas and research institutions have deployed or are in the process of evaluating. It's the best federated model one can get where the best expertise in drug development and testing comes together with the broadest range of combo candidates to see what can be brought to bear.
It's all pointing to the strategy of filing for Lung with Bavi/Doce closely followed by multiple filing for multiple indications through the various collaborations - should they produce the results we hope.
I agree 100% and I'd also find trouble finding one other small biotech that has took this route "before" partnering ?
Some can look at it two ways.... but there are many paths on why a small biotech ends up partnering with a Big Pharma, though it mostly is something that mostly all are "FORCED" into because of the lack of funds and knowing eventually, they are sincerely forced into some breadcrumb (borrowing CP's term..) deal, and many don't realize they are even being fed breadcrumbs until they see years later that their molecule or drug..etc is part of a Billion dollar mafia empire of Big Pharma.
Peregrine knows all this early on and they are thankfully, doing things that are unheard of ever before to take a road that is less traveled or should say never traveled before for a small biotech.
I like how you mentioned "insurance.." MH, because think of what Big Pharma knows and know imagine them just knowing that PS Targeting is not even in the hands of MSK/AZ but soon the game is wide open as it is left in the hands of hundreds of NCCN researchers that want to make a name for themselves as well. Who knows what is published one day from this collaboration and would one Big Pharma risk not taking control of the situation now and early on before one day they wake up to see PPHM rising and rising and all of a sudden having the leverage of just possibly buying out a few smaller size pharmas and they (a Gilead) possibly, losing out and coming so close to having PS Targeting under their roof.
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
Recent CDMO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM